retatrutide clinical trial results 2024 2025 press release Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide 2026: 28.3% Weight Loss

For a powerful class of drugs known as "biologics," delivering medicine in a pill was an extremely challenging scientific puzzle for almost a century

Multiple studies have investigated berberine's effect on GLP-1 secretion

Although the pathogenesis of PCOS has not been fully elucidated, recent studies have indicated that excess levels of androgens might be the main pathogenic causative factor of PCOS (144146)

It is estimated that GLP-1 released into the bloodstream contains 80% in the GLP-1 (736 amide) form and the remaining 20% is in the GLP-1 (737) form

The SURMOUNT-1 trial showed that tirzepatide produced even greater weight loss in many patients

Okunogbe, Nugent, Spencer)